Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Indivior (INDV.L) will delist from the London Stock Exchange effective July 25, maintaining its primary listing on the Nasdaq to cut costs and align with its U.S.-centric business. The opioid addiction treatment company, whose shares have fallen over 60% from 2018 highs, cites that over 80% of its revenue originates from the U.S., with approximately 75% of trading volume occurring on the Nasdaq. This move, following a primary listing shift to the U.S. last year and recent management changes, reflects a broader trend of companies leaving the London market for better valuations in the U.S.

Analysis

Indivior PLC is proceeding with the cancellation of its secondary listing on the London Stock Exchange, effective July 25, consolidating its public trading onto its primary Nasdaq listing. This strategic decision is driven by a desire to reduce operational costs and better reflect the company's significant U.S. business concentration, where over 80% of its revenue originates and approximately 75% of its recent trading volume occurs. This move follows Indivior's shift of its primary listing to the United States in the preceding year and aligns with a broader trend of companies departing London markets, often attributed to perceived lower valuations and weaker investor appetite compared to U.S. exchanges. Indivior's shares have notably declined by more than 60% since their peak in June 2018. The delisting also occurs subsequent to a recent overhaul in senior management, including the appointment of a new Chair and CEO, signaling a period of strategic refocus for the opioid addiction treatment specialist. The market's moderately positive sentiment towards Indivior concerning this development suggests an acceptance of the rationale behind streamlining its listing structure.

Key Decisions for Investors

• Investors holding Indivior on the LSE should prepare for the July 25 delisting and evaluate the implications for their holdings, including potential mechanisms for trading via the Nasdaq.
• The company's sharpened focus on the U.S. market, underscored by this delisting and its revenue/trading volume concentration, requires investors to closely monitor its performance and execution within this key geographic segment.
• Consider the potential for enhanced operational efficiency and cost savings stemming from the simplified listing structure, and assess how recent leadership changes might influence the company's ability to capitalize on its U.S.-centric strategy.